ArticleOncology letters2025
Short‑term efficacy assessment of brigatinib for the treatment of neurofibromatosis type 2: A retrospective study.
Zhi Lin et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it